Cannabis Cessation, Inflammatory Markers and Schizophrenia. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Romeo, Bruno; Lestra, Valentine; Martelli, Catherine; Benyamina, Amine; Hamdani, Nora
• Is Part Of: Journal of dual diagnosis. Volume 18:Issue 1(2022)
• Page Start: 33
• Page End: 41
• Publication Date: 2022-01-02
• Subjects: Schizophrenia -- cannabis use -- C-reactive protein -- low grade inflammation -- anti-inflammatory effect; Dual diagnosis -- Periodicals; Mental illness -- Treatment -- Periodicals; Substance abuse -- Treatment -- Periodicals; Diagnosis, Dual (Psychiatry) -- Periodicals; Substance-Related Disorders -- Periodicals; Mental Disorders -- Periodicals; 362.29
• DOI: 10.1080/15504263.2021.2013697
• Languages: English
• ISSNs: 1550-4263

Abstract

Abstract: Objective A dysbalance of the immune system in schizophrenia has been largely described but few studies have investigated the impact of cannabis use on inflammatory markers in patients with schizophrenia. The objective of our study was to investigate the impact of cannabis use on high-sensitivity C-reactive protein (hsCRP), fibrinogen levels and leucocytic formula in patients with schizophrenia. Methods: Thirty-eight acutely ill inpatients with schizophrenia were included. Patient hsCRP, fibrinogen levels, leukocytic formula and urinary cannabis were measured at baseline and after four weeks of treatment. Results: After four weeks of cannabis cessation (as confirmed by urinary tests), we found an increase of hsCRP level ( p = .016) and lymphocytes ( p = .03) in consumers patients whereas no difference was observed in non-consumers patients. As compared to non-consumers patients with schizophrenia, consumers had lower levels of hsCRP ( p = .045). Finally, a negative correlation was found between the PANSS score evolution (between baseline and 4 weeks) and baseline hsCRP level. Conclusions: In our study, cannabis cessation raises inflammatory markers though improving clinical symptoms. The investigation and the understanding of interactions between cannabis use and inflammatory markers in patients with schizophrenia is of importance and could in the future be a new target for treatment of psychiatric symptoms linked to inflammation.